Transcranial Random Noise Stimulation in Food Addiction Treatment (tRNS-FA)

January 6, 2020 updated by: Hôpital le Vinatier

Effect of Transcranial Random Noise Stimulation of Prefrontal Cortex on Craving Supply Subject Suffering From Obesity

Obesity is worldwide a public health problem. According to World Health Organization (WHO), overweight and obesity are the fifth death risk factor worldwide. At least 2.8 million adults die each year. Food addiction is one of the causes of obesity that may benefit from new therapeutic options.

Study Overview

Detailed Description

Transcranial random noise stimulation is a noninvasive brain stimulation technic. The modulation of the electrical activity of the right and left dorsolateral prefrontal cortex (DLPFC) by tRNS is able to act on the phenomenon of craving in other addictions. This allows us to make the assumption that tRNS stimulation could constitute a treatment for food addiction especially in obesity.

Study Type

Interventional

Enrollment (Actual)

13

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bron Cedex, France, 69678
        • Centre Hospitalier Le Vinatier

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Female or male between 18 and 65 years old
  • Patients suffering from obesity, with a BMI ≥ 30.
  • Food dependence score at the Yale Food addiction Scale ≥ 3

Exclusion Criteria:

  • Presence of a an other psychiatric diagnosis of Axis I (DSM IV);
  • Presence of addictive comorbidity other than food addiction
  • Psychotropic treatment;
  • Pregnancy or lactation;
  • Contraindication to fMRI .

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Active tRNS treatment

The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsalateral prefrontal cortex (F4).

100 (Hertz)Hz-650Hz, 2milliampere(mA), 30min, twice daily, 5 days

The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsolateral prefrontal cortex (F4).

100Hz-650Hz, 2mA, 30min, twice daily, 5 days

SHAM_COMPARATOR: Placebo tRNS treatment
The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effects on craving frequencies
Time Frame: Change from baseline after 3 months
by questionnaires scores and declarative number of food
Change from baseline after 3 months

Secondary Outcome Measures

Outcome Measure
Time Frame
change in body weight
Time Frame: Change from baseline after 3 months
Change from baseline after 3 months
change in waist circumference
Time Frame: Change from baseline after 3 months
Change from baseline after 3 months
change in body mass index
Time Frame: Change from baseline after 3 months
Change from baseline after 3 months
change in biological markers such as lipid profile, ghrelin, leptin, prolactin
Time Frame: Change from baseline after 3 months
Change from baseline after 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: D'AMATO THIERRY, PUPH, CH Le Vinatier

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 1, 2016

Primary Completion (ACTUAL)

April 30, 2019

Study Completion (ACTUAL)

May 2, 2019

Study Registration Dates

First Submitted

March 7, 2016

First Submitted That Met QC Criteria

March 17, 2016

First Posted (ESTIMATE)

March 23, 2016

Study Record Updates

Last Update Posted (ACTUAL)

January 9, 2020

Last Update Submitted That Met QC Criteria

January 6, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Overweight, Obesity and Other Hyperalimentation (E65-E68)

Clinical Trials on Active tRNS

3
Subscribe